Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 6/20 | 0.37 |
| ▸ | CES2 | O00748 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701069 | 0.98 | PPARA (0.40) | PPARATBXAS1LTB4RCES1CES2 | |
| SCHEMBL7169347 | 0.90 | LTB4R (0.39) | PPARATBXAS1LTB4RCES1CES2 | |
| SCHEMBL9321972 | 0.87 | PPARA (0.47) | PPARATBXAS1LTB4RCES1CES2 | |
| SCHEMBL6691110 | 0.84 | CES1 (0.39) | PPARACES1CES2L3MBTL1TDP1 | |
| SCHEMBL11782068 | 0.81 | CES1 (0.51) | PPARACES1CES2 | |
| SCHEMBL11664524 | 0.81 | CES1 (0.51) | PPARACES1CES2 | |
| SCHEMBL3282682 | 0.80 | L3MBTL1 (0.47) | PPARATBXAS1CES1CES2L3MBTL1 | |
| SCHEMBL6531463 | 0.79 | CES1 (0.42) | PPARALTB4RCES1CES2 | |
| SCHEMBL6350509 | 0.78 | PPARA (0.41) | PPARATBXAS1LTB4RCES1L3MBTL1 | |
| SCHEMBL1728463 | 0.78 | CES1 (0.52) | PPARACES1CES2TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004531459-A | — | — | 2004-10-14 | — | — | JP | claimed |
| US-20040122091-A1 | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-06-24 | — | — | US | claimed |
| US-6673780-B2 | SUCH AS 4-(4-(3-HYDROXY-3-METHYL-BUTANE-1-SULFINYLMETHYL)-PHENYLMETHANESULFINYL)-2 -METHYL-BUTAN1-OL FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES, DYSLIPIDEMIAS, DYSPROTEINEMIAS, AND GLUCOSE METABOLISM DISORDERS | ESPERION THERAPEUTICS, INC. | 2004-01-06 | — | — | US | claimed |
| EP-1366024-A2 | SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-12-03 | — | — | EP | claimed |
| WO-2002030882-A9 | SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2003-02-20 | — | — | WO | claimed |
| WO-2002030882-A2 | SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| US-6673780-B2 | SUCH AS 4-(4-(3-HYDROXY-3-METHYL-BUTANE-1-SULFINYLMETHYL)-PHENYLMETHANESULFINYL)-2 -METHYL-BUTAN1-OL FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES, DYSLIPIDEMIAS, DYSPROTEINEMIAS, AND GLUCOSE METABOLISM DISORDERS | ESPERION THERAPEUTICS, INC. | 2004-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122091-A1 | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses | NR1H2, NR1H3, APOB | PPARA 37/4885TBXAS1 405/4885LTB4R 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.